Viridian Therapeutics, Inc.\DE (VRDN) Amortizatization of Intangibles (2016 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Amortizatization of Intangibles came in at $1.9 million in Q1 2026, down 19.96% year-on-year from $2.3 million in Q1 2025, and up 5.93% quarter-over-quarter from $1.8 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Amortizatization of Intangibles history runs 11 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 19.96% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 52.71% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 56.83% from the prior year.
- Amortizatization of Intangibles climbed to $1.9 million in Q1 2026 per VRDN's latest filing, from $1.8 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $4.7 million in Q1 2024 and bottomed at -$274000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $2.3 million (2025), against an average of $2.1 million.
- Across the five-year window, Amortizatization of Intangibles surged 1415.54% in 2023 and slumped 66.45% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $937000.0 in 2022, then jumped by 227.32% to $3.1 million in 2023, then grew by 4.56% to $3.2 million in 2024, then tumbled by 45.34% to $1.8 million in 2025, then advanced by 5.93% to $1.9 million in 2026.
- Per Business Quant, the three latest VRDN Amortizatization of Intangibles figures stand at $1.9 million (Q1 2026), $1.8 million (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 655.26 Mn | 655.26 Mn | - | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Dec 31, 2023 | 3.07 Mn |